Prognostic value of cfDNA methylation in locally advanced esophageal squamous cell cancer treated with neoadjuvant immunochemoradiotherapy
Blood-based markers of cancer DNA may help predict treatment response in esophageal cancer, though larger studies are needed.
This PubMed-indexed observational/cohort study examined Prognostic value of cfDNA methylation in locally advanced esophageal squamous cell cancer treated with neoadjuvant immunochemoradiotherapy. The abstract reports that dynamic cfDNA methylation monitoring is associated with pCR and DFS, warranting further validation in larger cohorts.
What the study was
- Study design
- Observational/cohort study
- Population
- Prognostic value of cfDNA methylation in locally advanced esophageal squamous cell cancer treated with neoadjuvant immunochemoradiotherapy.
- Sample size
- 183
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- Cell reports. Medicine
Why it surfaced
Observational/cohort study with an abstract-supported finding relevant to Precision oncology and genomic medicine; scored conservatively because only the PubMed abstract was reviewed.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.